市场调查报告书
商品编码
1017200

全球血浆蛋白质治疗药市场:2021~2028年

Global Plasma Protein Therapeutics Market - 2021-2028

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

  • 全貌
  • 简介
  • 目录
简介

全球血浆蛋白质治疗药的市场规模在预测期间(2021年~2028年)预计将大幅成长。

血浆蛋白疗法可治疗各种医疗状况,恢复血浆中缺乏和缺乏的蛋白质,并帮助其接受者过上更健康、更有成效的生活。接受血浆蛋白治疗的患者通常需要终生定期输注。

本报告提供全球血浆蛋白质治疗药市场相关调查,提供市场概要,以及各产品,各用途,各地区的趋势,及加入此市场的主要企业简介等资讯。

目录

第1章 全球血浆蛋白质治疗药市场调查手法和范围

  • 调查手法
  • 调查的目的和调查范围

第2章 全球血浆蛋白质治疗药市场-市场定义和概要

第3章 全球血浆蛋白质治疗药市场-摘要整理

  • 各产品的市场明细
  • 各用途的市场明细
  • 各地区的市场明细

第4章 全球血浆蛋白质治疗药市场-市场动态

  • 影响市场的要素
    • 促进因素
    • 阻碍因素
    • 市场机会
    • 影响分析

第5章 全球血浆蛋白质治疗药市场-产业分析

  • 波特的五力分析
  • 市场机会
  • PEST分析
  • 供应链分析
  • 价格分析
  • 法规分析
  • 偿付分析
  • 未满足需求

第6章 全球血浆蛋白质治疗药市场-COVID-19分析

  • 市场上的COVID-19分析
    • COVID-19前的市场方案
    • COVID-19目前市场方案
    • COVID-19后或未来方案
  • COVID-19的价格动态
  • 需求与供给的频谱
  • 政府在COVID-19疫情下的市场相关措施
  • 制造商策略性举措
  • 结论

第7章 全球血浆蛋白质治疗药市场-各产品

    • 各产品区隔的市场规模分析,及与前一年同期比较成长分析(%)
    • 各产品区隔的市场魅力指数
  • 免疫球蛋白
    • 市场规模分析,一百万美元,2018~2028年,及与前一年同期比较成长分析(%)、2020~2028年
  • 白蛋白
  • 血浆原来第Viii因素
  • 其他

第8章 全球血浆蛋白质治疗药市场-各用途

    • 市场规模分析,及与前一年同期比较成长分析(%)、各用途
    • 各用途的市场魅力指数
  • 血友病
    • 市场规模分析,一百万美元,2018~2028年,及与前一年同期比较成长分析(%)、2020~2028年
  • 原发性免疫缺陷症(PID)
  • 特发性血小板减少紫斑症(ITP)
  • 其他

第9章 全球血浆蛋白质治疗药市场-各地区

    • 市场规模分析,一百万美元,2018~2028年,及与前一年同期比较成长分析(%)、2020~2028年,各地区
    • 各地区的市场魅力指数
  • 北美
    • 主要地区具体动态
    • 市场规模分析,及与前一年同期比较成长分析(%)、各产品
    • 市场规模分析,及与前一年同期比较成长分析(%)、各用途
    • 市场规模分析,及与前一年同期比较成长分析(%)、各国
  • 欧洲
    • 主要地区具体动态
    • 市场规模分析,及与前一年同期比较成长分析(%)、各产品
    • 市场规模分析,及与前一年同期比较成长分析(%)、各用途
    • 市场规模分析,及与前一年同期比较成长分析(%)、各国
  • 南美
    • 主要地区具体动态
    • 市场规模分析,及与前一年同期比较成长分析(%)、各产品
    • 市场规模分析,及与前一年同期比较成长分析(%)、各用途
    • 市场规模分析,及与前一年同期比较成长分析(%)、各国
  • 亚太地区
    • 主要地区具体动态
    • 市场规模分析,及与前一年同期比较成长分析(%)、各产品
    • 市场规模分析,及与前一年同期比较成长分析(%)、各用途
    • 市场规模分析,及与前一年同期比较成长分析(%)、各国
  • 中东和非洲
    • 主要地区具体动态
    • 市场规模分析,及与前一年同期比较成长分析(%)、各产品
    • 市场规模分析,及与前一年同期比较成长分析(%)、各用途

第10章 全球血浆蛋白质治疗药市场-竞争情形

  • 主要的发展与策略
  • 企业占有率分析
  • 产品的基准
  • 值得注意的主要企业
  • 颠覆性技术的企业
  • Start-Ups企业

第11章 全球血浆蛋白质治疗药市场-企业简介概要

  • Grifols S.A
    • 企业概要
    • 类型组合和概要
    • 主要的焦点
    • 财务概要
  • CSL Behring LLC
  • Octapharma AG
  • Shire Plc
  • Biotest AG
  • Kedrion S.P.A
  • China Biologics Products Holdings, Inc
  • Takeda Pharmaceutical Company Ltd
  • Baxter International Ltd
  • ADMA Biologics, Inc
  • Chengdu inst
  • Hualan Bio
  • Shuanglin Bio
  • Tiantan Bio
  • Shanghai RAAS Blood Products

清单并未网罗全面

第12章 全球血浆蛋白质治疗药市场-DataM

  • 附录
  • 关于本公司·服务
  • 咨询方式
目录
Product Code: DMPH3497

Market Overview

The global plasma protein therapeutics market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Plasma protein therapy treats different medical conditions, restoring missing or inadequate proteins found in plasma to allow their receivers to lead healthier and more productive lives. The patients that rely upon plasma protein therapies generally require regular infusions for the duration of their lives.

Market Dynamics

The plasma protein therapeutics market growth is driven by the growing prevalence of autoimmune disorders, immune deficiency disorders, neurological and bleeding disorders, the rising awareness about plasma donation is a major reason for market growth as elderly people are more prone to neurological disorders, growing investements in research and development programs by the biotechnology and pharmaceutical companies is boosting the market growth, the advancements in the plasma proteins.

The rising awareness about plasma donation, is expected to drive the global plasma protein therapeutics market growth

The awareness about plasma donation is increasing every year, more than 22 million liters of plasma are utilized to manufacture life-saving medicines to treat more than one million people worldwide. For instance, Baxter works closely with the Plasma Protein Therapeutics Association, or PPTA, to raise awareness of the importance of plasma donation to support a growing, global need for plasma-derived therapies. In 2011, Baxter received approval in Europe to use immune globulin to treat for multifocal motor neuropathy, a neurological disease that attacks the peripheral nerves, resulting in progressive limb weakness. In addition, Baxter also is in clinical trials exploring the use of immune globulin as a treatment for Alzheimer's disease.

Growing investments in research and development programs, is expected to drive the global plasma protein therapeutics market growth

The plasma protein industry players have been investing in the research and development of new plasma protein therapies (e.g., Ceruloplasmin, IgA, Plasmin), leading to innovative treatments for the benefit of patients. For instance, in March 2016, Grifols Biologicals, LLC invested US$ 360 Mn to extend production capabilities for plasma-derived therapies. This investment will increase the plasma fractionation capacity and purification of several proteins. This has also been evident from advancements such as the product presentations (e.g., subcutaneous IG, IVIG 10% concentration, and IVIG liquid presentation), manufacturing process (e.g., improvement of yield), added virus elimination technologies (e.g., nanofiltration), and development of new plasma proteins (e.g., protein C and purified factor V).

Stringent regulation and reimbursement issues threat is likely to hamper the growth of the market

The stringent regulation and reimbursement issues threat may restrict the market growth as plasma collection standards in emerging countries do not match those required by the fractionators. These regions follow stringent rules and regulations regarding the quality of their operations, starting with the quality of the raw material. Specific fractionators are designed for plasma. For example, the European health authorities require that the plasma pool for fractionation be tested for HIV, hepatitis A, B and C, and Parvovirus B. The blood collected by many centers is often unable to comply with these regulations, causing some recovered plasma to be unused.

Moreover, health budgets have been subjected to rising pressures. Funding through reimbursement pathways from private and public payers has come under inspection. It has drawn plasma protein therapies into the landscape of Health Technology Assessments (HTA), including the possible application of cost-utility analysis (CUA) to distribute reimbursement funds and, given the high cost of the therapies and the comparatively nascent nature of many indications, the application of these tools of health economics can constrain the supply of products for patients in genuine need.

In addition, regulatory and quality policies affect every step of the plasma protein therapy life cycle, including donor safety, quality and compliance, the biological license application process, therapy safety and efficacy, and pharmacovigilance. For example, licensing and inspecting plasma collection centers and plasma protein therapy manufacturing facilities can be tedious and time-consuming.

COVID-19 Impact Analysis

The COVID-19 outbreak is expected to have a major impact on the market. In the context of the COVID-19 pandemic, government organizations in various countries, research institutes, and many biotech and pharmaceutical firms are focusing on practical and rapid technologies for the fast diagnosis of COVID-19 and developing vaccines and novel therapeutics to overcome the current situation. It is also affecting the global economy in three main ways: by directly affecting production and demand, creating supply chain and market disruption, and its economic impact on the companies and financial markets. The present COVID-19 pandemic has also temporarily impacted plasma donation globally, affecting the plasma protein therapeutics market. However, researchers focus on plasma-based therapeutics to identify whether these therapies have any promising role in treating the COVID-19 virus. For example, in April 2020, Kamada Ltd. and Kedrion Biopharma, two biopharmaceutical companies specialized in plasma-derived protein therapeutics, entered into a global collaboration for the development, manufacturing, and distribution of a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a most potential treatment for COVID patients.

Moreover, in April 2020, the Indian Council of Medical Research (ICMR) pursued the participation of researchers for conducting a clinical trial of convalescent plasma therapy to treat critically ill COVID-19 patients and floated a protocol for it. In May 2020, BioAegis Therapeutics started researching its lead product, recombinant human plasma gelsolin therapy (rhu-pGSN), believing it as a viable therapeutic option for patients suffering from severe lung injury due to COVID-19.

Segment Analysis

The Immunoglobulin segment is expected to hold largest share in this market segment

Many clinical indications for IG have been rapidly growing. Immuno globulins have become an important treatment option in many clinical indications beyond significant immunodeficiency, including autoimmune and acute inflammatory conditions and also, off-label prescribing has crossed over into almost every medical specialty. In addition, the chronic use of off-label prescribing in some indications, particularly for the treatment of some neurological illnesses, in addition to immune deficiencies, is increasing the demand for IGs.

Plasma-derived immunoglobulin is used for a wide range of autoimmune and inflammatory diseases. Increased recognition and treatment of immune deficiencies in the developing world have added to the global demand for IG. However, increased use of high-dose therapy, particularly in autoimmune neurologic diseases, is the primary reason for the continued strong demand for IG products.

Widespread off-label use of IG demonstrates the use of a large volume of plasma. Examples of the most common off-label uses for IVIG in the U.S include

  • Multifocal motor neuropathy (MMN)
  • Acute panautonomic polyneuropathy
  • Hemolytic disease of the newborn
  • Autoimmune mucocutaneous blistering diseases and
  • Acute cardiomyopathy.

This clinical demand for medicines has increased in the past few years, and the trend is likely to continue due to constant improvement in diagnosis and improved life-expectancy.

For instance, in March 2018, the first immunoglobulin therapy received approval from the FDA is developed by CSL's Hizentra. It is highly used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

The Hemophilia segment is expected to hold largest share in this market segment

Hemophilia, a unique bleeding disorder of genetic origin that prevents normal blood clotting holds large share of the market segment. The primary symptom of this disorder is uncontrolled and often causes spontaneous bleeding in distinct areas of the body. The amount of bleeding depends on the severity of hemophilia. For instance, according to the World Federation of Hemophilia report 2019, the number of people identified with hemophilia increased from 78,629 in 1999 to 210,454 in 2018. Additionally, as per the Global Hemophilia Care 2019 report, more than 1,125,000 men worldwide have an inherited bleeding disorder, and 418,000 of those have an extreme version of the most undiagnosed disease. Hemophilia A type is the most prevalent condition, with an incidence rate of 1 in 4,000 to 1 in 5,000 males worldwide born with this disorder. Hemophilia B occurs in approximately 1 in 20,000 newborn males across the world. The increasing prevalence of hemophilia and the vast patient pool are expected to trigger market growth during the forecast period.

Moreover, the increasing R&D research on developing new therapeutics and product launches is expected to boost the segment growth over the forecast period. For instance, in October 2018, the United States Food and Drug Administration (FDA) approved Roche's Hemlibra for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, newborns and older, with hemophilia A without factor VIII inhibitors. The increasing geriatric population is also expected to boost demand for plasma protein therapeutics.

Geographical Analysis

North America region holds the largest market share of global plasma protein therapeutics market

The North American region is expected to serve a large share of the plasma protein therapeutics market due to factors like the rising prevalence of autoimmune diseases and neurological disorders. The United States is expected to have the largest share in this region.

The existence of the well-established healthcare infrastructure-focused market players on R&D for plasma protein therapeutics, coupled with recent product launches, and the rising burden of autoimmune disorders are major growth factors for the market in the United States. According to the Centers for Disease Control and Prevention (CDC), in 2018, about 70% of people with hemophilia in the United States receive multidisciplinary, comprehensive care in a network of federally funded hemophilia treatment centers. In addition, according to the United States Arthritis Foundation, arthritis is the leading cause of disability among adults. About 54 million adults were diagnosed with arthritis by conservative estimates. In addition, almost 300,000 children have arthritis or rheumatic condition (as of 2017-2018) and, according to a study published by Derek Weycker, in October 2019, the annual prevalence of immune thrombocytopenia (ITP) in the United States was 6.1 per 100,000 persons, higher among females than males (6.7 vs. 5.5), and the highest among children aged between 0 and 4 years (8.1) and adults aged 65 years and above (13.7).

Furthermore, there has been an increased focus on convalescent plasma therapy to treat COVID-19 in the United States. For instance, in April 2020, Johns Hopkins got FDA approval to test blood plasma therapy to treat COVID-19 patients. In addition, the US FDA issued guidance to provide recommendations for investigational convalescent plasma therapy. Hence, the market for plasma protein therapeutics is boosted to have major growth in the United States.

The increasing geriatric population in this region also increases the patient pool, like older people are more prone to neurological diseases. Furthermore, beneficial government initiatives, escalating awareness levels among the blood donors, advanced protein fractioning procedures, greater per capita income in developed countries, and increased research partnerships are some of the drivers expected to increase market growth in the region.

Competitive Landscape

The global plasma protein therapeutics market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include CSL Behring LLC, Octapharma AG, Grifols S.A., Shire Plc, Biotest AG, Kedrion S.P.A., China Biologics Products Holdings, Inc., Takeda Pharmaceutical Company Ltd., Baxter International Ltd, ADMA Biologics, Inc, Chengdu inst, Hualan Bio, Shuanglin Bio, Tiantan Bio, Shanghai RAAS Blood Products. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, In February 2021, Biotest became the first plasma protein manufacturer in Germany to produce an investigational hyper immunoglobulin preparation against COVID-19.

Key Companies to Watch

Grifols S.A

Overview: Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world. They are industry leader in producing plasma-derived medicines and transfusion medicine. They sell their products and services in more than 100 countries and regions and have subsidiaries in more than 30 of them. They have 24,000 employees work for a common goal to improve people's lives and well-being.

Product Portfolio: The company is focused primarily on Bioscience, Diagnostic, Hospital, and Bio Supplies.

Product: Plasmanate (Plasma Protein Fraction (Human) 5%, USP)

Protein solution comprised of approximately 88% normal human albumin, 12% alpha and beta globulins, and not more than 1% gamma globulin.

Indications: Plasmanate is indicated in the treatment of shock due to burns, crushing injuries, abdominal emergencies.

Key Development: On June 1st 2021, Grifols introduced HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B.

Why Purchase the Report?

  • Visualize the composition of the plasma protein therapeutics market segmentation by Product, Application highlighting the key commercial assets and players.
  • Identify commercial opportunities in plasma protein therapeutics market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of plasma protein therapeutics market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global plasma protein therapeutics market report would provide an access to an approx. 53 market data table, 44 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Plasma Protein Therapeutics Market - By Product

  • Immunoglobulin
  • Albumin
  • Plasma Derived Factor Viii
  • Others

Global Plasma Protein Therapeutics Market - By Application

  • Hemophilia
  • Primary Immunodeficiency Disorder (PID)
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Others

Global Plasma Protein Therapeutics Market - By Region

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa
  • South America

Table of Contents

1. Global Plasma Protein Therapeutics Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Plasma Protein Therapeutics Market - Market Definition and Overview

3. Global Plasma Protein Therapeutics Market - Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Region

4. Global Plasma Protein Therapeutics Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. The rising awareness about plasma donation
      • 4.1.1.2. Growing investments in research and development programs
    • 4.1.2. Restraints:
      • 4.1.2.1. Stringent regulation and reimbursement issues
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Plasma Protein Therapeutics Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Opportunities
  • 5.3. PEST Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. Global Plasma Protein Therapeutics Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Plasma Protein Therapeutics Market - By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
    • 7.1.2. Market Attractiveness Index, By Product Segment
  • 7.2. Immunoglobulin*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Albumin
  • 7.4. Plasma Derived Factor Viii
  • 7.5. Others

8. Global Plasma Protein Therapeutics Market - By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Hemophilia*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Primary Immunodeficiency Disorder (PID)
  • 8.4. Idiopathic Thrombocytopenic Purpura (ITP)
  • 8.5. Others

9. Global Plasma Protein Therapeutics Market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10. Global Plasma Protein Therapeutics Market - Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking
  • 10.4. Key Companies to Watch
  • 10.5. Company with disruptive technology
  • 10.6. Start Up Companies

11. Global Plasma Protein Therapeutics Market- Company Profiles

  • 11.1. Grifols S.A*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. CSL Behring LLC
  • 11.3. Octapharma AG
  • 11.4. Shire Plc
  • 11.5. Biotest AG
  • 11.6. Kedrion S.P.A
  • 11.7. China Biologics Products Holdings, Inc
  • 11.8. Takeda Pharmaceutical Company Ltd
  • 11.9. Baxter International Ltd
  • 11.10. ADMA Biologics, Inc
  • 11.11. Chengdu inst
  • 11.12. Hualan Bio
  • 11.13. Shuanglin Bio
  • 11.14. Tiantan Bio
  • 11.15. Shanghai RAAS Blood Products

LIST NOT EXHAUSTIVE

12. Global Plasma Protein Therapeutics Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us